Login to Your Account

Agennix Nosedives on Surprise Ph III Lung Cancer Drug Failure

By Nuala Moran
Staff Writer

Wednesday, August 8, 2012
LONDON – Agennix AG has reached the devastation point with the Phase III failure of its lead product talactoferrin in a 742-patient Phase III trial in lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription